临床进展再生元公告简讯
再生元公布garetosmab治疗FOP的3期OPTIMA试验84周结果：新异位骨化病灶为零
再生元公布garetosmab治疗成人FOP的3期OPTIMA试验84周结果，garetosmab组未观察到新异位骨化病灶，安慰剂组为9个。OPTIMA试验入组63名18岁及以上FOP患者，58人完成双盲延展期至至少84周。
原文标题：Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension